FDA has approved Ozempic for this, in the words of each label below. FLOW (Semaglutide): In people with type 2 diabetes and chronic kidney disease, major kidney events or death from kidney or heart causes were 24% less likely on semaglutide (331 against 410 first events; hazard ratio 0.76). ClinicalTrials.gov lists 68 trials of these medicines on it: 14 with posted results and 16 recruiting now.
Read from the registry and PubMed every day. The newest update here is Nov 5, 2026.
The approved use, word for word from each current label.
Each read in the paper's abstract on Nov 6, 2026. Trials differ in who took part and how long they ran.
Semaglutide · 3,533 people · Better than the comparison · Placebo-controlled randomized trial
In people with type 2 diabetes and chronic kidney disease, major kidney events or death from kidney or heart causes were 24% less likely on semaglutide (331 against 410 first events; hazard ratio 0.76).
A trial counts when the registry's conditions or title name this, and some study a related question, such as insulin sensitivity in people with the condition. A registered trial shows a question being asked, not that the answer is yes.
| Medicine | Trials | Posted results | Recruiting |
|---|---|---|---|
| Semaglutide | 34 | 5 | 14 |
| Exenatide | 7 | 3 | 0 |
| Liraglutide | 7 | 2 | 0 |
| Dulaglutide | 5 | 2 | 0 |
| Retatrutide | 4 | 0 | 0 |
| Tirzepatide | 4 | 1 | 1 |
| Orforglipron | 3 | 1 | 1 |
| Mazdutide | 2 | 0 | 0 |
| Survodutide | 2 | 0 | 0 |
Latest phases and largest trials first. Each result is the first primary outcome as its sponsor posted it to the registry, which is not peer review.
| Trial | Medicine | Phase | People | Result |
|---|---|---|---|---|
| FLOWA Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease | Semaglutide | Phase 3 | 3,533 | Number of Participants From Time of Randomization to First Occurrence of Onset of Persistent ≥50% Reduction in eGFR(CKD-EPI); Onset of Persistent eGFR(CKD-EPI) <15mL/Min/1.73m^2; Initiation of Chronic Renal Replacement Therapy; Renal Death; CV Death (Participants), From Week 0 up to Week 234. Semaglutide: 331; Placebo: 410. |
| AWARD-7A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD) | Dulaglutide | Phase 3 | 577 | Change From Baseline in Hemoglobin A1c (HbA1c) (percentage of HbA1c), Baseline, 26 Weeks. Insulin Glargine: -1.13; Dulaglutide 0.75 mg: -1.12; Dulaglutide 1.5 mg: -1.19. |
| PIONEER 5Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes and Moderate Renal Impairment | Semaglutide | Phase 3 | 324 | Change in HbA1c (Percentage of HbA1c), Week 0, week 26, In-trial. Oral Semaglutide 14 mg: -1.1; Placebo: -0.2. |
| NCT01620489Efficacy and Safety of Liraglutide Versus Placebo as add-on to Existing Diabetes Medication in Subjects With Type 2 Diabetes and Moderate Renal Impairment | Liraglutide | Phase 3 | 279 | Estimated Mean From the Statistical Model and Standard Deviation From Observed Data For Change From Baseline to Week 26 in HbA1c (%) (Glycosylated Haemoglobin) (percentage (%)), Week 0, Week 26. Lira 1.8 mg: -1.05; Placebo: -0.38. |
| REMODELA Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (the REMODEL Trial) | Semaglutide | Phase 3 | 106 | Change in Kidney Oxygenation (Cortex), Blood Oxygenation-level Dependent Magnetic Resonance Imaging (BOLD MRI) (R2*) (Ratio of kidney oxygenation (cortex)), Baseline (week 0), End of treatment (week 52), Bilateral cortex. Semaglutide 1.0 mg: 0.98; Placebo: 1.00. |
| NCT02251431Extended Release Exenatide Versus Placebo In Diabetic Patients With Type 4 Cardiorenal Syndrome | Exenatide | Phase 3 | 57 | Galectin-3 (pg/ml), 38 weeks, Baseline. Exenatide-extended Release: 9570.91; Placebo: 9266.7. |
| NCT01847313The Effect of Glucagon-like-peptide 1 (GLP-1) Receptor Agonism on Diabetic Kidney Disease | Liraglutide | Phase 3 | 20 | MCP-1:Creatinine Ratio in Urine (ng/mmol), Up to 26 weeks. Liraglutide: 27.9; Control: 24.3. |
| RAISE-KTEffect of Subcutaneous Semaglutide on Kidney Transplant Candidacy | Semaglutide | Phase 3 | 15 | Kidney Transplant Eligibility (Participants), Ascertained at the end of 9 months. Semaglutide: 3; Placebo: 2. |
| 1981GLP-1 Receptor Agonist Therapy and Albuminuria in Patients With Type 2 Diabetes | Exenatide | Phase 4 | 15 | Change From Baseline in Urinary Albuminuria Levels (microgram/mg creatinine), baseline and 52 weeks. Exenatide Extended Release: -32; Placebo: -12. |
| NCT04515849A Study of Cotadutide in Participants Who Have Chronic Kidney Disease With Type 2 Diabetes Mellitus | Semaglutide | Phase 2 | 248 | The Primary Endpoint Was Percentage Change in UACR of Cotadutide at Different Dose Levels Compared to Placebo After 14 Weeks (Percentage change), Baseline to the end of 14 weeks of dosing. Cotadutide 100 ug: -10.96; Cotadutide 300 µg: -40.47; Cotadutide 600 µg: -44.60; Placebo ug: 4.60. |
| NCT03961256Assess the Efficacy and Safety of Exenatide SR for the Prevention of Diabetes After Kidney Transplantation | Exenatide | Phase 2 | 9 | Progression From Prediabetes to Diabetes (Participants), 12 months after transplantation. Exenatide SR Intervention Group: 0; Standard of Care: 1. |
| GLIMPEffects of GLP1-RA on Ectopic Fat Deposition in Chronic Kidney Disease | Dulaglutide | Phase 2 | 7 | On ClinicalTrials.gov |
| NCT03482024A Study of Tirzepatide (LY3298176) in Participants With Impaired Kidney Function | Tirzepatide | Phase 1 | 45 | Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of Tirzepatide From Time Zero to Tlast (AUC[0-tlast]) (Nanogram*hour per Millilitre (ng*h/mL)), Predose, 8hours(h), 12h, 24h, 48h, 72h, 96h, 168h, 336h postdose. Tirzepatide - Control: 78400; Tirzepatide - Mild Renal Impairment: 81900; Tirzepatide - Moderate Renal Impairment: 98300; Tirzepatide - Severe Renal Impairment: 81200; Tirzepatide - End Stage Renal Disease (ESRD): 88500. |
| NCT05936138A Phase 1, Parallel, Single-Dose, Open-Label, Single-Period Study of LY3502970 in Participants With Normal Renal Function and Participants With Renal Impairment. | Orforglipron | Phase 1 | 24 | Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC0-∞) of LY3502970 (nanogram*hour per milliliter (ng*hr/mL)), Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72 and 96 hours postdose. LY3502970 (Normal Renal Function): 113; LY3502970 (Severe Renal Impairment): 167; LY3502970 (End-Stage Renal Disease): 108. |
The registry page names each site and who can enroll. Ask your clinician before joining one.
The 15 largest of 16 recruiting.
Randomized trial · Nat Med · Oct 1, 2026 · Tuttle KR et al.
Meta-analysis · Diabetes Obes Metab · Sep 13, 2026 · Perry F et al.
Meta-analysis · Eur Heart J Qual Care Clin Outcomes · Sep 1, 2026 · Ahmed M et al. · cited by 2
Randomized trial · Lancet Diabetes Endocrinol · Aug 7, 2026 · Mann JFE et al. · cited by 2
Meta-analysis · Endocr Pract · Aug 4, 2026 · Dutta D et al.
Meta-analysis · Diabetes Obes Metab · Jun 25, 2026 · Hasebe M et al. · cited by 1
Listed from Europe PMC as published, newest first. A listing here is not a judgement of a study's quality or a recommendation.
Written from each source's own record as it changes. Every change on GLPcompare
FLOW (Semaglutide, 3,533 people): In people with type 2 diabetes and chronic kidney disease, major kidney events or death from kidney or heart causes were 24% less likely on semaglutide (331 against 410 first events; hazard ratio 0.76).
Yes: Ozempic. Ozempic's label: to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes mellitus and chronic kidney disease.
Plans decide, and they usually tie coverage to a medicine's approved uses, so Ozempic is the place to start. Ask your plan whether it covers the medicine for this diagnosis and whether it needs prior authorization.
Semaglutide, with 34 registered trials on it, then Exenatide with 7. More trials do not mean better results: read what each posted.
16 trials are recruiting on ClinicalTrials.gov now, listed below with their registry pages, which name each site and who can enroll.